Toward autophagy-targeted therapy in lymphoma

Abstract

In this issue of Blood, Gayle et al provide evidence that apilimod, a potent and selective phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, induces significant cytotoxicity at clinically achievable concentrations in preclinical models of B-cell non-Hodgkin lymphoma (NHL) via inhibition of the autophagy flux and perturbation of lysosome homeostasis.1